

Esperite N.V. (ESP): Additional delays needed on the publication of the Annual Report 2017.

Amsterdam, The Netherlands – 18 July 2018

Following earlier information provided regarding the delay on the publication of the Annual Report 2017 mainly due to technical issues which have now been identified, Esperite regrets to inform that the issuance of the Annual Report will be further delayed despite the effort spent over the last months.

Esperite N.V will communicate as soon as a release date is foreseen.

About ESPERITE

ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.

To learn more about the *ESPERITE* Group, or to book an interview with CEO Frédéric Amar: <u>+31 575 548 998</u> - <u>ir@esperite.com</u> or visit the websites at <u>www.esperite.com</u>, <u>www.genoma.com</u> and <u>www.cryo-save.com</u>.

This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014 (Market Abuse Regulation).